A Philadelphia jury delivered a landmark verdict Tuesday against Janssen Pharmaceuticals Inc. and Bayer Healthcare Pharmaceuticals Inc., awarding $27.8 million to an Indiana woman who suffered a gastrointestinal bleed linked to her use of the blood-thinner Xarelto.
The jury found the drugmakers provided inadequate warnings about the risks of bleeding events associated with Xarelto, awarding Lynn Hartman $1.8 million in actual damages and $26 million in punitive damages.
This verdict comes after juries earlier this year found in favor of the drugmakers in three federal multidistrict litigation (MDL) Xarelto trials. There are more than 1,500 Xarelto-related cases pending in the Philadelphia County Court of Common Pleas and more than 19,000 cases pending in the Xarelto MDL in the Eastern District of Louisiana.
Lynn Hartman v. Janssen Pharmaceuticals Inc.
Hartman was hospitalized in 2014 with a gastrointestinal bleed after using Xarelto to reduce her risk of stroke from atrial fibrillation. She spent four days in the hospital and received multiple transfusions after losing more than 40 percent of her blood volume.
The lawsuit against Janssen Pharmaceuticals Inc. and Bayer Healthcare Pharmaceuticals Inc. claimed the drugmakers failed to include information on Xarelto’s warning label indicating that a higher rate of bleeding events was observed in clinical trials in the U.S. compared to patients around the world. Evidence presented in the case showed the rate among U.S. clinical trial participants was 8.1 percent annually versus just 3.6 percent for patients globally.
The attorneys representing Hartman also accused the drugmakers of failing to provide adequate warnings that the risk of a bleeding event is higher when Xarelto is used while also taking aspirin, as well as failing to inform doctors that some patients end up with significantly higher levels of Xarelto in their blood than other patients.
Former U.S. Food & Drug Administration chief David Kessler was among those who testified in the trial. He said in his testimony that he believed the Xarelto warning label understated the drug’s risk, leaving out key information on the severity of potential bleeding risks.
Janssen Pharmaceuticals Inc. is a subsidiary of Johnson & Johnson, which developed Xarelto jointly with Bayer AG. Xarelto is among the companies’ top-selling drugs, generating $3.2 billion in sales last year for Bayer and $2.3 billion for Johnson & Johnson.
Get Xarelto Lawsuit Help
Emily Jeffcott has been heavily involved in all of the Xarelto trial work, including participating as trial counsel in the preceding trials. She has taken depositions all over the world in preparation for this particular trial, briefing the countless issues that arose and overall contributing to a great victory for individuals, like Ms. Hartman, who were harmed by this drug company’s punitive conduct.
If you suffered serious side effects from Xarelto use, contact The Lambert Firm today at (800) 521-1750 to schedule a free consultation.